Harvard Bioscience (HBIO) Stock Statistics & Valuation Metrics

Harvard Bioscience has a market cap or net worth of $25.21M. The enterprise value is $62.24M.

Harvard Bioscience has 4,510,182 shares outstanding. The number of shares has decreased by -2.65% in one year.

Harvard Bioscience’s return on equity (ROE) is -4.13 and return on invested capital (ROIC) is -1.04%.

The current PE Ratio of Harvard Bioscience is ―. Harvard Bioscience’s PEG ratio is -0.00147.

In the last 12 months, Harvard Bioscience had revenue of 86.55M and earned -56.70M in profits. Earnings per share was -12.80.

In the last 12 months, operating cash flow was 2.83M and capital expenditures -1.31M, giving a free cash flow of 1.51M billion.

Harvard Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Harvard Bioscience upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Harvard Bioscience as a current ratio of 2.20, with Debt / Equity ratio of 439.20%

In the past 12 months, Harvard Bioscience has paid -686.00K in taxes.

Harvard Bioscience EV to EBITDA ratio is 12.30, with an EV/FCF ratio of 11.64.

Harvard Bioscience has $7.10M in cash and marketable securities with $44.12M in debt, giving a net cash position of -$37.02M billion.

Gross margin is 57.06%, with operating margin of -0.73%, and net profit margin of -65.51%.

The average price target for Harvard Bioscience is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy